These data suggest that pirtobrutinib treatment initially inhibits the BCR signaling pathway in CLL patients irrespective of their BTK status; however, this inhibition was reversed after one cycle of therapy. Here, BTK is linked to B-cell chronic lymphocytic leukemia.